Ascus Biosciences

Ascus Biosciences is an animal microbiome company develops computational and genomics-based technology platform to discover and develop next-generation microbial products.

Ascus is focused on discovering, developing, and commercializing first-in-class endomicrobial products for the animal health and nutrition industries.

Ascus Biosciences was founded in 2015 by Michael Seely, Mallory Embree and Karsten Zengler. The company is headquartered in San Diego, California.

 

Ascus is pioneering the emerging science of endomicrobial ecology to illuminate microbial communities within animals, and the role they play in overall health and performance. It has a broad pipeline of all-natural, endomicrobial products in development across livestock and companion animals.

 

Ascus uses its proprietary technology platform to resolve the complexities in the native microbial communities living in highly productive and healthy animals. From these curated insights, efficacious native microorganisms are selected and isolated from animal samples and developed into products.

 

Ascus Biosciences is backed by Temasek, Anterra Capital, Formation 8, Cavallo Ventures and others. The company raised $46M in Series B round on May 27, 2020. This brings Ascus' total funding to $63.5M to date.

 

 

  • Year founded: 2015
  • Funding Info: $63.5M over 3 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: San Diego
  • State: California
  • Country: United States
Related businesses